Upregulation of Somatostatin Receptor Type 2 Expression in Neuroendocrine Tumors by Epigenetic Modulation

#976

Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment of neuroendocrine tumors (NETs). However, epigenetic mechanisms might account for the high variability in sst2 expression and treatment response between patients.

Aim(s): Determine expression of sst2 in NET cell line BON and NET tissues, as well as the effect of the demethylating agent 5-aza-2’-deoxycytidine (5-aza-dC) and histone deacetylase inhibitor Valproic Acid (VPA) on sst2 expression and epigenetic modifications in BON.

Materials and methods: BON cells were exposed four days to IC50 of 5-aza-dC or VPA. Sst2 mRNA values were determined by Q-RT-PCR, CpG methylation by pyrosequencing and H3K9 acetylation by chromatin immunoprecipition (ChIP). Sst2 mRNA expression and promoter methylation was also determined in 18 NETs.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Veenstra M, Van Koetsveld P, Farrell W, Dogan F, Waaijers A,

Keywords: GEP-NET, sst2, epigenetics,